Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PH-762 · 1 trial · 3 indications
Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events.
| Arm | Type | Description |
|---|---|---|
| Sequential escalating doses of PH-762. | EXPERIMENTAL | Escalating doses of PH-762 are to be tested, with an observation period between doses. |
| Name | Type | Description |
|---|---|---|
| PH-762 | DRUG | PH-762 is a potent RNAi molecule targeting PD-1. |
Key Inclusion Criteria: * Histologically confirmed cutaneous squamous cell carcinoma (cSCC), melanoma, or Merkel cell carcinoma, meeting one of the following criteria: * cSCC, resectable local tumors: must be Stage II or lower, amenable to curative resection and in a location where acceptable su...
PH-762 is an investigational small molecule being developed for the treatment of Squamous Cell Carcinoma of the Skin. It is also being studied in other cutaneous malignancies, including Malignant Melanoma of the Skin and Merkel Cell Carcinoma of the Skin, as part of an ongoing clinical trial.
PH-762 targets PD-1, a gene involved in immune regulation. By targeting PD-1, the drug is designed to modulate the immune response against cancer cells. This mechanism is being evaluated in the context of cutaneous malignancies, including squamous cell carcinoma of the skin.
PH-762 is being developed by Phio Pharmaceuticals Corp., a biopharmaceutical company listed on the stock exchange under the ticker symbol PHIO. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug in patients with certain skin cancers.
PH-762 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of the drug in patients with cutaneous carcinomas.
PH-762 is being studied in a Phase 1 clinical trial with the identifier NCT06014086, titled 'Intratumoral PH-762 for Cutaneous Carcinoma.' The trial is active but not recruiting, with an estimated enrollment of 30 participants. It is an uncontrolled, open-label study being conducted in the United States.
PH-762 is a distinct investigational small molecule that targets PD-1. While it shares a molecular target with other PD-1 inhibitors, it is a unique drug candidate developed by Phio Pharmaceuticals. No alternative names for PH-762 have been disclosed in the available clinical trial information.